COVID-19 vaccine effectiveness against severe disease from SARS-CoV-2 Omicron BA.1 and BA.2 subvariants – surveillance results from southern Sweden, December 2021 to March 2022-Reference-Cited by-同舟云学术

COVID-19 vaccine effectiveness against severe disease from SARS-CoV-2 Omicron BA.1 and BA.2 subvariants – surveillance results from southern Sweden, December 2021 to March 2022

Published:2022-05-05 Issue:18 Volume:27 Page:
ISSN:1560-7917
Container-title:Eurosurveillance
language:en
Short-container-title:

Author:

Björk Jonas¹²^ORCID,Bonander Carl³^ORCID,Moghaddassi Mahnaz⁴^ORCID,Rasmussen Magnus⁵^ORCID,Malmqvist Ulf¹,Inghammar Malin⁵^ORCID,Kahn Fredrik⁵^ORCID

Affiliation:

1. Division of Occupational and Environmental Medicine, Lund University, Lund, Sweden

2. Clinical Studies Sweden, Forum South, Skåne University Hospital, Lund, Sweden

3. School of Public Health and Community Medicine, Institute of Medicine, University of Gothenburg, Gothenburg, Sweden

4. Social Medicine and Global Health, Department of Clinical Sciences Malmö, Lund University, Malmö, Sweden

5. Department of Clinical Sciences Lund, Section for Infection Medicine, Skåne University Hospital, Lund University, Lund, Sweden

Abstract

We compared vaccine effectiveness against severe COVID-19 between December 2021 and March 2022 when Omicron BA.1 and BA.2 were the dominating SARS-CoV-2 variants in Scania county, Sweden. Effectiveness remained above 80% after the transition from BA.1 to BA.2 among people with at least three vaccine doses but the point estimate decreased markedly to 54% among those with only two doses. Protection from prior infection was also lower after the transition to BA.2. Booster vaccination seems necessary to maintain sufficient protection.

Publisher

European Centre for Disease Control and Prevention (ECDC)

Subject

Virology,Public Health, Environmental and Occupational Health,Epidemiology

Reference10 articles.

1. Transmission of SARS-CoV-2 Omicron VOC subvariants BA.1 and BA.2: Evidence from Danish households.;Lyngse;medRxiv,2022.01.28.22270044

2. COVID-19 Vaccine Effectiveness against the Omicron BA.2 variant in England.;Kirsebom;medRxiv,2022.03.22.22272691

3. Effect of prior infection, vaccination, and hybrid immunity against symptomatic BA.1 and BA.2 Omicron infections and severe COVID-19 in Qatar.;Altarawneh;medRxiv,2022.03.22.22272745

4. High level of protection against COVID-19 after two doses of BNT162b2 vaccine in the working age population - first results from a cohort study in Southern Sweden.;Björk;Infect Dis (Lond),2022

5. Risk of severe COVID-19 from the Delta and Omicron variants in relation to vaccination status, sex, age and comorbidities - surveillance results from southern Sweden, July 2021 to January 2022.;Kahn;Euro Surveill,2022

Cited by 40 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Characterization of the SARS-CoV-2 antibody landscape in Norway in the late summer of 2022: high seroprevalence in all age groups with patterns of primary Omicron infection in children and hybrid immunity in adults;BMC Infectious Diseases;2024-08-20

2. Antibody‐mediated control mechanisms of viral infections;Immunological Reviews;2024-08-20

3. Mismanagement of SARS-CoV-2 Infection Pre Hospitalisation during the Omicron Era: Antibiotics and Steroids Instead of Early Antivirals;Viruses;2024-06-22

4. COVID-19 Vaccine Uptake and Effectiveness by Time since Vaccination in the Western Cape Province, South Africa: An Observational Cohort Study during 2020–2022;Vaccines;2024-06-05

5. Neutralization antibody titer and change in 50% protection after the third dose of the COVID-19 vaccine;Indian Journal of Pharmacology;2024-03